Claims for Patent: 7,179,816

Summary for Patent: 7,179,816

Title:	Chemical derivatives and their application as antitelomerase agents
Abstract:	The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
Inventor(s):	Mailliet; Patrick (Fontenay sous Bois, FR), Riou; Jean-Francois (Reims, FR), Alasia; Marcel (Choisy le Roi, FR), Caulfield; Thomas (Paris, FR), Doerflinger; Gilles (Les Ulis, FR), Mergny; Jean-Louis (Villejuif, FR), Laoui; Abdelazize (Bridgewater, NJ), Petitgenet; Odile (Paris, FR), Renou; Emmanuelle (Paris, FR)
Assignee:	Aventis Pharma S.A. (Antony, FR)
Application Number:	10/954,808
Patent Claims:	1. A compound which binds the G-quadruplex structure of a telomere comprising the following general formula: nitrogen-containing aromatic ring --NR.sub.3-- distribution agent --NR'.sub.3-- nonaromatic hydrocarbon chain wherein 1) the nitrogen-containing aromatic ring represents: a) a quinoline optionally substituted with i) a group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a C1 C4 alkyl radical or ii) a group ORa in which Ra is as defined above b) a quinoline possessing a nitrogen atom in quaternary form c) a benzamidine or d) a pyridine, 2) R.sub.3 and R'.sub.3, which are identical or different, represent independently of each other, hydrogen or a C1 C4 alkyl radical, 3) the distribution agent represents: a pyrimidine group, or a pyrimidine group substituted with (i) an alkyl radical having 1 to 4 carbon atoms, (ii) a thiol radical, (iii) a hydroxy radical, or (iv) an amino radical substituted with one or more short-chain alkyl groups containing 1 to 4 carbon atoms, wherein the alkyl, thiol, or hydroxy radicals are unsubstituted or substituted with one or more short-chain alkyl groups containing 1 to 4 carbon atoms or wherein the alkyl is unsubstituted or substituted with a halogen atom, or a salt thereof. 2. The compound according to claim 1, wherein the nonaromatic hydrocarbon chain is chosen from among i) alkyl (C1 C4), alkenyl (C2 C4), wherein the alkyl and alkenyl are linear or branched, ii) cycloalkyl (C3 C18) iii) cycloalkenyl (C3 C18) iv) heterocycloalkyl (C3 C18) and v) heterocycloalkyl (C3 C18) including the nitrogen atom of the NR'.sub.3 group. 3. The compound according to claim 2, wherein the nonaromatic hydrocarbon chain is unsubstituted or substituted with one or more atoms or radicals chosen from among halogen atoms, hydroxyl, aryl, heteroaryl, alkyloxy, aryloxy, thiol, alkylthio, arylthio, amino, alkylamino, arylamino, dialkylamino, diarylamino, amidino, guanidino, alkylcarbonylamino, arylcarbonylamino, carboxyl, alkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyl, arylcarbonyl, cyano, trifluoromethyl, and combinations thereof. 4. The compound according to claim 3, wherein the alkyl chains comprise substituents having a hydrocarbon chain containing 1 to 4 carbon atoms, and the aryl groups comprise substituents having a hydrocarbon chain containing 5 to 18 carbon atoms. 5. The compound according to claim 2, wherein the alkyl chains contain 2 to 3 carbon atoms, and the heterocycloalkyl or cycloalkyl chains contain 5 to 7 carbon atoms. 6. A therapeutic composition comprising a compound according to claim 1 and one or more anticancer compounds. 7. The composition according to claim 6, wherein the one or more anticancer compounds are chosen from among alkylating agents, platinum derivatives, antibiotic agents, antimicrotubule agents, anthracyclines, group I and II topoisomerases, fluoropyrimidines, cytidine analogs, adenosine analogs, L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, irinotecan, topotecan, dexrazoxane, amifostine, herceptin, estrogenic hormones, and androgenic hormones. 8. A method of treating a breast cancer, comprising administering a therapeutically effective amount of one or more compounds of claim 1 to a patient in need of such a treatment, wherein the level of telomerase activity following the administration is reduced relative to the level of telomerase activity existing prior to the administration. 9. A pharmaceutical composition comprising one or more compounds of claim 1, and a pharmaceutically acceptable carrier. 10. A method of treating breast cancer, comprising administering to a patient in need of such treatment an effective amount of one or more compounds according to claim 1 in combination with radiation.

Details for Patent 7,179,816

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2021-01-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2021-01-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2021-01-09